Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 75
1.
Opt Lett ; 42(18): 3682-3685, 2017 Sep 15.
Article En | MEDLINE | ID: mdl-28914932

We report on the direct experimental observation of the 7pP23/2→7dD2 optical transitions in 209 and 210 francium isotopes. By continuously monitoring the fluorescence emitted by the isotopes collected in a magneto-optical trap (MOT), the electric dipole transitions 7pP23/2→7dD25/2 of Fr209, not yet experimentally observed, and 7pP23/2→7dD25/2, 7pP23/2→7dD25/2 of Fr210 were detected as sub-Doppler depletion dips of the cold atom population. This approach allowed unambiguous identification of the excited state hyperfine structures, even in the absence of a large stable vapor. Our findings demonstrate the effectiveness and the flexibility of fluorescence monitoring of trap depletion upon laser excitation, and broaden the experimental knowledge of francium isotopes and their electronic and nuclear properties. These results will have a relevant impact on ongoing researches for low-energy testing of fundamental symmetries with francium, from atomic parity non-conservation to the electron dipole moment.

2.
Eur J Clin Microbiol Infect Dis ; 35(7): 1187-93, 2016 Jul.
Article En | MEDLINE | ID: mdl-27142585

Previous studies have shown that the high dose of gentamicin (8 mg/kg) rarely achieves the desired peak plasma concentration (Cmax) of ≥30 mg/l in patients with severe sepsis or septic shock. The aim of this study was to determine the first dose of gentamicin needed to achieve a Cmax ≥ 30 mg/l. We conducted a prospective observational cohort study in one intensive care unit. All consecutive patients hospitalized for severe sepsis or septic shock and treated with a first dose of gentamicin >6 mg/kg were evaluated. During the study period, 15 of the 57 patients (26.3 %) treated with gentamicin had a Cmax ≥ 30 mg/l. The median dose of gentamicin administered was 8.9 [7.8-9.9] mg/kg. Independent factors in the multivariate analysis associated with a Cmax ≥ 30 mg/l were higher body mass index (per kg/m(2) increment) (OR: 1.173, 95%CI: 1.015-1.356, P = 0.03) and higher first dose of gentamicin (per mg/kg increment) (OR: 2.343, 95%CI: 1.346-4.08, P = 0.003). The optimal first dose to achieve a Cmax ≥ 30 mg/l was 11 mg/kg, with a specificity and a sensitivity of 100 % and 53.3 % respectively. These results suggest that a first dose of gentamicin >11 mg/kg is needed to achieve a Cmax ≥ 30 mg/l in most patients.


Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Gentamicins/administration & dosage , Gentamicins/pharmacokinetics , Sepsis/drug therapy , Aged , Comorbidity , Drug Monitoring , Female , Hospitalization , Humans , Intensive Care Units , Male , Middle Aged , Prognosis , Risk Factors , Sepsis/diagnosis , Sepsis/mortality , Severity of Illness Index , Shock, Septic/diagnosis , Shock, Septic/drug therapy , Treatment Outcome
3.
Phys Rev Lett ; 115(17): 172503, 2015 Oct 23.
Article En | MEDLINE | ID: mdl-26551108

Absolute cross sections for isotopically identified products formed in multinucleon transfer in the (136)Xe+(198)Pt system at ∼8 MeV/nucleon are reported. The isotopic distributions obtained using a large acceptance spectrometer demonstrated the production of the "hard-to-reach" neutron-rich isotopes for Z<78 around the N=126 shell closure far from stability. The main contribution to the formation of these exotic nuclei is shown to arise in collisions with a small kinetic energy dissipation. The present experimental finding corroborates for the first time recent predictions that multinucleon transfer reactions would be the optimum method to populate and characterize neutron-rich isotopes around N=126 which are crucial for understanding both astrophysically relevant processes and the evolution of "magic" numbers far from stability.

4.
J Chem Phys ; 141(13): 134201, 2014 Oct 07.
Article En | MEDLINE | ID: mdl-25296799

We present here the first evidence of photodesorption induced by low-intensity non-resonant light from an yttrium thin foil, which works as a neutralizer for Rb and Fr ions beam. Neutral atoms are suddenly ejected from the metal surface in a pulsed regime upon illumination with a broadband flash light and then released in the free volume of a pyrex cells. Here atoms are captured by a Magneto-Optical Trap (MOT), which is effectively loaded by the photodesorption. Loading times of the order of the flash rise time are measured. Desorption is also obtained in the continuous regime, by exploiting CW visible illumination of the metallic neutralizer surface. We demonstrate that at lower CW light intensities vacuum conditions are not perturbed by the photodesorption and hence the MOT dynamics remains unaffected, while the trap population increases thanks to the incoming desorbed atoms flux. Even with the Y foil at room temperature and hence with no trapped atoms, upon visible illumination, the number of trapped atoms reaches 10(5). The experimental data are then analyzed by means of an analytical rate equation model, which allows the analysis of this phenomenon and its dynamics and allows the determination of critical experimental parameters and the test of the procedure in the framework of radioactive Francium trapping. In this view, together with an extensive investigation of the phenomenon with (85)Rb, the first demonstration of the photodesorption-aided loading of a (210)Fr MOT is shown.

5.
Phys Rev Lett ; 113(5): 052501, 2014 Aug 01.
Article En | MEDLINE | ID: mdl-25126912

An excitation function of one- and two-neutron transfer channels for the ^{60}Ni+^{116}Sn system has been measured with the magnetic spectrometer PRISMA in a wide energy range, from the Coulomb barrier to far below it. The experimental transfer probabilities are well reproduced, for the first time with heavy ions, in absolute values and in slope by microscopic calculations which incorporate nucleon-nucleon pairing correlations.

6.
Phys Rev Lett ; 113(2): 022701, 2014 Jul 11.
Article En | MEDLINE | ID: mdl-25062170

Measurements of the excitation function for the fusion of (24)Mg+(30)Si (Q=17.89 MeV)have been extended toward lower energies with respect to previous experimental data. The S-factor maximum observed in this large, positive-Q-value system is the most pronounced among such systems studied thus far. The significance and the systematics of an S-factor maximum in systems with positive fusion Q values are discussed. This result would strongly impact the extrapolated cross sections and reaction rates in the carbon and oxygen burnings and, thus, the study of the history of stellar evolution.

7.
Int J Immunopathol Pharmacol ; 26(3): 801-6, 2013.
Article En | MEDLINE | ID: mdl-24067481

Buckwheat allergy is considered a rare food allergy outside of Asia. In Europe, buckwheat has been described mainly as a hidden allergen. Data on the prevalence of buckwheat hypersensitivity in non-Asian countries is very poor. The aim of this multicenter study was to evaluate the prevalence of buckwheat sensitization and its association with other sensitizations among patients referred to allergy clinics in different geographic areas of Italy. All patients referred to 18 Italian allergy clinics from February through April 2011 were included in the study and evaluated for sensitization to buckwheat and other allergens depending on their clinical history. A total of 1,954 patients were included in the study and 61.3 percent of them were atopic. Mean prevalence of buckwheat sensitization was 3.6 percent with significant difference between Northern (4.5 percent), Central (2.2 percent) and Southern (2.8 percent) regions. This is, to our knowledge, the largest epidemiological survey on buckwheat allergy reported outside of Asia. Buckwheat is an emerging allergen in Italy, being more frequently associated to sensitization in Northern regions.


Allergens , Fagopyrum/adverse effects , Food Hypersensitivity/epidemiology , Adult , Female , Food Hypersensitivity/diagnosis , Food Hypersensitivity/immunology , Humans , Italy/epidemiology , Male , Middle Aged , Predictive Value of Tests , Prevalence , Referral and Consultation , Skin Tests , Young Adult
8.
Diabet Med ; 29(1): 24-31, 2012 Jan.
Article En | MEDLINE | ID: mdl-21781149

AIMS: To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy. METHODS: After a 4-week placebo period, patients were randomized to losartan 50 mg (n = 90) or amlodipine 5 mg (n = 91) for 12 months, with a doubling of the dose in patients who did not respond after 4 weeks. Blood pressure was measured in the clinic every month, while conventional echocardiography and acoustic densitometry (integrated backscatter analysis) were performed at the end of the placebo period and after 12 months of treatment. RESULTS: Both drugs reduced systolic/diastolic blood pressure to a comparable extent. Losartan significantly reduced left ventricular mass index (-19%, P < 0.001), interventricular septal thickness (-16.6%, P < 0.01) and left ventricular posterior wall thickness in diastole (-13.7%, P < 0.01). Amlodipine also decreased such measurements (-10%, P < 0.01 for left ventricular mass index, -9.3%, P < 0.05 for interventricular septal thickness in diastole and -10.1%, P < 0.05 for posterior wall thickness in diastole), but to a lesser extent than losartan. Both drugs significantly increased the ratio of peak filling velocity at early diastole to that at atrial contraction (E/A ratio) and decreased isovolumetric relaxation time: +13.7% and -8.5% with losartan,(both P < 0.01), and +7.9% and -4.9%, with amlopidine (both P < 0.05). Losartan, but not amlodipine, significantly reduced the relative integrated backscatter compared to baseline of the intraventricular septum (-10%, P < 0.01), and of the left ventricular posterior wall (-12%, P < 0.01), while increasing the cyclic variation of integrated backscatter of both the intraventricular septum (+35%, P < 0.001) and the left ventricular posterior wall (+32%, P < 0.001). CONCLUSIONS: Losartan provided a greater attenuation of left ventricular hypertrophy than amlodipine, seemingly as a result of a greater reduction of myocardial fibrosis.


Amlodipine/therapeutic use , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Diabetic Angiopathies/drug therapy , Hypertension/drug therapy , Hypertrophy, Left Ventricular/prevention & control , Losartan/therapeutic use , Ventricular Dysfunction, Left/prevention & control , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/physiopathology , Diabetic Angiopathies/etiology , Diabetic Angiopathies/physiopathology , Diastole/drug effects , Echocardiography , Female , Fibrosis/drug therapy , Humans , Hypertension/complications , Hypertension/physiopathology , Hypertrophy, Left Ventricular/etiology , Male , Middle Aged , Myocardium/pathology , Prospective Studies , Treatment Outcome , Ventricular Dysfunction, Left/etiology
9.
Phys Rev Lett ; 102(24): 242502, 2009 Jun 19.
Article En | MEDLINE | ID: mdl-19659003

The lifetimes of the first excited states of the N = 30 isotones (50)Ca and (51)Sc have been determined using the Recoil Distance Doppler Shift method in combination with the CLARA-PRISMA spectrometers. This is the first time such a method is applied to measure lifetimes of neutron-rich nuclei populated via a multinucleon transfer reaction. This extends the lifetime knowledge beyond the f_{7/2} shell closure and allows us to derive the effective proton and neutron charges in the fp shell near the doubly magic nucleus (48)Ca, using large-scale, shell-model calculations. These results indicate an orbital dependence of the core polarization along the fp shell.

10.
Opt Lett ; 34(7): 893-5, 2009 Apr 01.
Article En | MEDLINE | ID: mdl-19340162

An interferometric method is used to improve the accuracy of the 7S-7P transition frequencies of three francium isotopes by 1 order of magnitude. The deduced isotope shifts for 209-211Fr confirm the ISOLDE data. The frequency of the D2 transition of 212Fr--the accepted reference for all Fr isotope shifts--is revised, and a significant difference with the ISOLDE value is found. Our results will be a benchmark for the accuracy of the theory of Fr energy levels, a necessary step to investigate fundamental symmetries.

11.
J Hum Hypertens ; 18(10): 687-91, 2004 Oct.
Article En | MEDLINE | ID: mdl-15071488

The aim of this double-blind, double-dummy, parallel group study was to compare the effects of delapril-manidipine combination vs a irbesartan-hydrochlorothiazide combination on plasma tissue plasminogen activator (t-PA) and plasmogen activator inhibitor type I (PAI-l) activities in hypertensive patients with type II diabetes mellitus. After a 4-week run-in placebo period, 80 patients (37 male and 43 female), aged 41-65 years, were randomly allocated to an 8-week treatment with delapril 30 mg once daily or irbesartan 150 mg once daily. Thereafter, manidipine l0 mg once daily was added to delapril treatment and hydrochlorothiazide 12.5 mg to irbesartan treatment for a further 8 weeks. Blood pressure (BP), plasma t-PA and PAI-l activities were evaluated at the end of the run-in period, after 4-week monotherapy treatments, and at the end of the combination treatment periods. Both combination treatments, delapril-manidipine and irbesartan-hydrochlorothiazide, produced a greater reduction in systolic BP/diastolic BP (SBP/DBP) values (-27.6/21.8 mmHg and -26.4/20.2 mmHg, respectively) than the respective monotherapies (-15.2/11.7 mmHg with delapril and -16.3/11.3 mmHg with irbesartan). Delapril monotherapy significantly decreased plasma PAI-l activity (-10.4 IU/mI; P<0.05). The addition of manidipine produced a significant increase in t-PA activity (+0.27 IU/mI); P<0.05). Irbesartan monotherapy did not significantly affect the fibrinolytic balance, whereas the addition of hydrochlorothiazide worsened it, producing a significant increase in PAI-l activity (+9.5 IU/ml; P<0.05). In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it.


Antihypertensive Agents/therapeutic use , Diabetes Mellitus, Type 2/complications , Fibrinolysis/drug effects , Hypertension/drug therapy , Adult , Aged , Biphenyl Compounds/therapeutic use , Dihydropyridines/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/therapeutic use , Hypertension/complications , Indans/therapeutic use , Irbesartan , Male , Middle Aged , Nitrobenzenes , Piperazines , Plasminogen Activator Inhibitor 1/blood , Tetrazoles/therapeutic use , Tissue Plasminogen Activator/blood , Treatment Outcome
12.
Occup Environ Med ; 61(2): 163-6, 2004 Feb.
Article En | MEDLINE | ID: mdl-14739383

AIMS: To identify possible work related sources of psychosocial stress in order to develop pertinent questionnaire items for a cross-sectional health survey of 3000 Italian women flight attendants, and to solicit suggestions on improving survey participation. METHODS: Qualitative study in which 26 current and former women flight attendants participated: three focus groups of 6-7 participants each and six in-depth individual interviews. The session themes included positive and negative aspects of the job; relationships with colleagues, superiors, and passengers; perception of occupational risk for serious diseases; compatibility of work and family; and experiences of work related sources of stress and their effect on health. A transcript based analysis of the focus groups and interviews was used to identify emerging themes related to risk factors for mental health problems. RESULTS: The participants indicated that mental health was a major concern. Several work related risk factors possibly related to adverse outcomes, such as depression and anxiety, were highlighted. These included isolation and solitude, fears of being inadequate partners and mothers due to job demands, passenger relationships, and lack of protection by employers with respect to workplace exposures and violent passengers. The information gained was used to develop a mental health module for inclusion in the health survey questionnaire which included questions on history of severe depression or anxiety, suicidal ideation or attempt, substance abuse, workplace sexual harassment, social support, leisure time activities, relationship with a partner, and role as mother. CONCLUSIONS: Employing qualitative methods to identify work related sources of psychosocial stress enabled development of pertinent questionnaire items for a cross-sectional epidemiological study of women flight attendants. Follow up qualitative research may be necessary in order to put the cross-sectional study findings into context and to explore actions or strategies for preventing work related health problems evidenced from the survey.


Aerospace Medicine/methods , Occupational Diseases/etiology , Stress, Psychological/etiology , Adult , Cross-Sectional Studies , Female , Focus Groups , Health Surveys , Humans , Interview, Psychological/methods , Occupational Health , Occupational Medicine/methods , Risk Factors
13.
J Hypertens ; 19(6): 1021-7, 2001 Jun.
Article En | MEDLINE | ID: mdl-11403349

OBJECTIVE: Studies on the effects of chronic exposure to industrial noise on clinic blood pressure (BP) at rest have yielded inconsistent results. The aim of this study was to evaluate the effect of occupational noise exposure on ambulatory blood pressure (ABP) in normotensive subjects. METHODS: We studied 476 normotensive workers, aged 20-50 years (systolic blood pressure (SBP) < 140, diastolic blood pressure (DBP) < 90), at a metallurgical factory; 238 were exposed to high levels of noise (> 85 dB), while 238 were not exposed (< 80 dB). Clinical evaluation included measurements of casual BP (by standard mercury sphygmomanometer, Korotkoff sound phase I and V) and heart rate (HR) (by pulse palpation), body height and weight. All subjects underwent a 24 h non-invasive ABP monitoring (by SpaceLabs 90207 recorder; SpaceLabs, Redmond, Washington, USA) twice within 14 days: one during a normal working day and one during a non-working day. Measurements were performed every 15 min. Computed analysis of individual recordings provided average SBP, DBP and HR values for 24 h, daytime working hours (0800-1700 h), daytime non-working hours (1700-2300 h) and night-time (2300-0800 h). RESULTS: No significant difference in clinic SBP, DBP and HR was observed between exposed and non-exposed subjects. Results obtained by ABP monitoring showed in the exposed workers: (a) a higher SBP (by a mean of 6 mmHg, P < 0.0001 versus controls) and DBP (by a mean of 3 mmHg, P < 0.0001) during the time of exposure and the following 2 or 3 h, whereas no difference between the two groups was found during the non-working day; (b) an increase in HR, which was present not only during the time of exposure to noise (+3.7 beats-per-minute (bpm), P < 0.0001 versus controls), but also during the non-working hours (+2.8 bpm, P < 0.001) and during the day-time hours of the non-working day (+2.8 bpm, P < 0.003); (c) a significant increase in BP variability throughout the working day. CONCLUSIONS: These findings suggest that in normotensive subjects below the age of 50 years, chronic exposure to occupational noise is associated with a transient increase in BP, which is not reflected in a sustained BP elevation. The possible role of repeated BP and HR fluctuations due to frequent and prolonged exposure to noise in accounting for the higher prevalence of hypertension reported in noise-exposed workers above age 50 years, requires longitudinal studies to be clarified.


Blood Pressure , Hypertension/etiology , Noise/adverse effects , Occupational Exposure , Adult , Blood Pressure Monitoring, Ambulatory , Case-Control Studies , Diastole , Heart Rate , Humans , Hypertension/physiopathology , Male , Middle Aged , Systole
14.
Am J Hypertens ; 14(1): 27-31, 2001 Jan.
Article En | MEDLINE | ID: mdl-11206674

The aim of this study was to compare the effect of antihypertensive treatment with valsartan or cavedilol on sexual activity in hypertensive men who were never treated for hypertension. A total of 160 newly diagnosed hypertensive men (diastolic blood pressure [DBP] > or = 95 mm Hg and < 110 mm Hg), aged 40 to 49 years, all married and without any previous sexual disfunction, were enrolled. After a 4-week placebo period, the patients were divided into two groups: a) 120 patients were randomized to receive carvedilol 50 mg once daily or valsartan 80 mg once daily for 16 weeks according to a double-blind, cross-over design; after another 4-week placebo period, patients were crossed over to the alternative regimen for a further 16 weeks; b) 40 patients were treated with placebo according to a single-blind design for 16 weeks. At the screening visit and every 4 weeks thereafter, blood pressure (BP) was evaluated and patients were interviewed by a questionnaire about their sexual activity. Blood pressure was significantly lowered by both treatments, with a 48% of normalization with valsartan and 45% with carvedilol. During the first month of therapy, sexual activity (assessed as number of sexual intercourse episodes per month) declined with both drugs as compared with baseline, although the decrease was statistically significant in the carvedilol (from 8.2 to 4.4 sexual intercourse episodes, P < .01) but not in the valsartan-treated patients (from 8.3 to 6.6 sexual intercourse episodes, not significant). Ongoing with the treatment the sexual activity further worsened with carvedilol (3.7 sexual intercourse episodes per month) while fully recovered and also improved with valsartan (10.2 sexual intercourse episodes per month). The results were confirmed by the cross-over. Erectile dysfunction was a complaint of 15 patients with carvedilol (13.5%), one patient with valsartan (0.9%), and one patient in the placebo group. These findings suggest that carvedilol induces a chronic worsening of sexual activity, whereas valsartan not only does not significantly worsen sexual activity but may even improve it.


Antihypertensive Agents/therapeutic use , Carbazoles/therapeutic use , Hypertension/drug therapy , Hypertension/physiopathology , Propanolamines/therapeutic use , Sexual Behavior/drug effects , Tetrazoles/therapeutic use , Valine/analogs & derivatives , Valine/therapeutic use , Adult , Antihypertensive Agents/adverse effects , Carbazoles/adverse effects , Carvedilol , Cross-Over Studies , Double-Blind Method , Humans , Male , Middle Aged , Propanolamines/adverse effects , Valsartan
15.
J Ethnopharmacol ; 74(1): 17-40, 2001 Jan.
Article En | MEDLINE | ID: mdl-11137345

An ethnobotanical survey was carried out in the year 1997-1998, in the neighbourhood of the town of Chieti in the Abruzzo region (Central Italy). The information recorded in this paper has been collected by interviewing people born in the area, or who have lived there for many years, and whose knowledge of the medicinal or domestic use of plants represents a personal patrimony uninfluenced by other sources. About 80 species claimed as medicinal (not only in human therapy but also, for example, in veterinary use) and belonging to 43 families are recorded; only the use of the plants identified with certainty is reported. The study pointed out that the heritage of medicinal popular use of such plants, in spite of pharmaceutical technology, is still alive, not only in the memory of the elders and farmers, and that nowadays home-made remedies for simple diseases are still often used: Moreover, the uses of these plants are not only limited to therapeutic purposes, but also extend to domestic and surviving craft activities.


Ethnobotany , Phytotherapy , Plants, Medicinal/therapeutic use , Animals , Female , Humans , Italy , Veterinary Medicine
16.
Rev Med Chil ; 128(1): 59-63, 2000 Jan.
Article Es | MEDLINE | ID: mdl-10883523

BACKGROUND: Third generation beta blockers have an intrinsic simpatico-mimetic activity and are cardioselective. Therefore, they should not have adverse bronchial effects and could even have a slight bronchodilator activity. AIM: To test the efficacy and safety of celiprolol in hypertensive patients with chronic obstructive lung disease. PATIENTS AND METHODS: Uncomplicated hypertensive patients with chronic obstructive lung disease received celiprolol during 12 weeks. They were subjected to monthly clinical assessment and ventilatory function was measured on the basal period and at the end of the trial. RESULTS: During the study period, blood pressure fell significantly from 179 +/- 6/112 +/- 8 to 161 +/- 4.7/98 +/- 1.6 mmHg. No changes were observed in forced expiratory volume in 1 s or in forced expiratory flow between 25 and 75% of the vital capacity. No subjective changes in respiratory function were reported during the trial. CONCLUSIONS: No changes in ventilatory function were observed in these patients with chronic obstructive lung disease, treated with celiprolol during 12 weeks.


Adrenergic beta-Antagonists/therapeutic use , Antihypertensive Agents/therapeutic use , Celiprolol/therapeutic use , Hypertension/drug therapy , Lung Diseases, Obstructive/drug therapy , Adrenergic beta-Antagonists/adverse effects , Aged , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Case-Control Studies , Celiprolol/adverse effects , Female , Humans , Hypertension/complications , Lung/drug effects , Lung Diseases, Obstructive/complications , Male , Middle Aged , Spirometry
17.
J Hypertens ; 18(12): 1871-5, 2000 Dec.
Article En | MEDLINE | ID: mdl-11132613

OBJECTIVE: The aim of this study was to compare the chronic effects of four dihydropyridine calcium antagonists with different pharmacologic characteristics, amlodipine, felodipine, lacidipine and manidipine,on blood pressure (BP), heart rate (HR) and plasma norepinephrine (NE) levels in patients with mild to moderate essential hypertension. METHOD: After a 4-week placebo period, 60 patients of both sexes were randomly administered amlodipine 5-10 mg once daily (o.d.) (n = 15); felodipine 5-10 mg o.d. (n = 15); lacidipine 4-6 mg o.d. (n = 15); manidipine 10-20 mg o.d. (n = 15), for 24 weeks, according to a double blind, parallel group design. Initially, for the first 2 weeks, the lowest dose of each drug was used, then higher doses were administered if sitting diastolic blood pressure (DBP) was > 90 mmHg. BP, HR and plasma NE were evaluated at the end of the placebo and active treatment periods. NE was assessed at trough, at peak and after 12 h from drug ingestion. RESULTS: Administration of all four drugs reduced clinic BP to the same level after 24 weeks, whereas HR increased only with felodipine (+ 3.1 bpm; P< 0.05). Significant increases in plasma NE levels were observed after chronic therapy with amlodipine and felodipine (+ 34.9 and + 39.4% respectively; P< 0.01 versus placebo) but not with lacidipine (+ 7.1%, NS) and manidipine (+ 2.9%, NS). CONCLUSIONS: These findings suggest that sympathetic activation occurred during chronic treatment with amlodipine and felodipine, whereas manidipine and lacidipine did not increase plasma noradrenaline at the times measured. The reasons for this difference are unclear; they could be related to the different pharmacological characteristic of the two drugs, lacidipine and manidipine.


Antihypertensive Agents/therapeutic use , Calcium Channel Blockers/therapeutic use , Dihydropyridines/therapeutic use , Hypertension/blood , Hypertension/drug therapy , Norepinephrine/blood , Adult , Aged , Amlodipine/therapeutic use , Blood Pressure/drug effects , Double-Blind Method , Felodipine/therapeutic use , Female , Heart Rate/drug effects , Humans , Hypertension/physiopathology , Male , Middle Aged , Nitrobenzenes , Piperazines , Sympathetic Nervous System/drug effects , Sympathetic Nervous System/physiopathology
18.
Cardiovasc Drugs Ther ; 13(3): 243-8, 1999 May.
Article En | MEDLINE | ID: mdl-10439887

To evaluate the effect of manidipine 10 mg on 24-hour ambulatory blood pressure (BP) and heart rate (HR) in very elderly hypertensive patients, 54 patients aged 76-89 years (mean age 81.8 years) with systolic blood pressure (SBP) > 160 mmHg and diastolic blood pressure (DBP) > 90 mmHg were studied. After a 4-week placebo washout period, patients were randomized to receive manidipine 10 mg or placebo, both administered once daily for 8 weeks. Patients were checked after the initial run-in placebo phase and every 4 weeks thereafter. At each visit casual BP and HR were measured. At the end of the placebo period and after 8 weeks of active treatment, noninvasive 24-hour ambulatory blood pressure measurement (ABPM) was performed. Manidipine significantly lowered casual sitting and standing SBP (P < 0.001) and DBP (P < 0.001) at the trough level. ABPM showed a significant decrease in 24-hour SBP and DBP values (P < 0.001), daytime SBP and DBP (P < 0.001), and night-time SBP (P < 0.001) and DBP (P < 0.005). In addition, ABPM confirmed a consistent antihypertensive activity throughout the 24-hour dosing interval, without effect on the circadian BP profile. The trough/peak ratio was 0.67 for SBP and 0.59 DBP. No statistically significant change in HR was observed. The treatment was well tolerated, and there were no serious side effects. In conclusion, in very elderly hypertensive patients, once-daily administration of manidipine 10 mg was well tolerated and effective in reducing casual as well ambulatory BP.


Antihypertensive Agents/administration & dosage , Calcium Channel Blockers/administration & dosage , Dihydropyridines/administration & dosage , Hypertension/drug therapy , Hypertension/physiopathology , Aged , Aged, 80 and over , Blood Pressure/drug effects , Blood Pressure/physiology , Blood Pressure Monitoring, Ambulatory , Double-Blind Method , Drug Administration Schedule , Female , Heart Rate/drug effects , Humans , Male , Nitrobenzenes , Piperazines , Placebos
19.
J Cardiovasc Pharmacol ; 33(4): 534-9, 1999 Apr.
Article En | MEDLINE | ID: mdl-10218722

The aim of this study was to compare the effects of long-term monotherapy with four different beta-blockers on plasma lipids in hypercholesterolemic hypertensive patients. We studied 152 subjects with essential hypertension [diastolic blood pressure (DBP) >90 mm Hg], total cholesterol (TC) >240 and <330 mg/dl, and triglycerides (TGs) <300 mg/dl. After a 4-week washout period with placebo, patients were randomized to receive propranolol, 160 mg/day (n = 37), atenolol, 100 mg/day (n = 38), bisoprolol, 10 mg/day (n = 39), or celiprolol, 400 mg/day (n = 38), for 18 months. No cholesterol-reducing drug was allowed. Blood samples for evaluation of TC, low-density lipoprotein cholesterol (LDL-C), HDL cholesterol (HDL-C), and TGs were taken before and after the placebo period and subsequently every 6 months. No beta-blocker worsened TC or LDL-C. Nonselective propranolol caused the most pronounced changes in HDL-C and TGs. Beta1-Selective atenolol produced the same qualitative effects, but to a lesser extent. The more beta1-selective bisoprolol did not affect HDL-C and TGs. Celiprolol significantly improved the lipid profile by significantly decreasing TC, LDL-C, and TGs, and increasing HDL-C. These findings suggest that in hypercholesterolemic hypertensive patients, (a) beta1-selective beta-blockers are likely to adversely affect plasma lipids to a lesser extent than nonselective ones; and (b) celiprolol is able to improve the lipid pattern, which could be because of its peculiar ancillary properties.


Adrenergic beta-Antagonists/therapeutic use , Hypercholesterolemia/drug therapy , Hypertension/drug therapy , Lipids/blood , Adrenergic beta-Agonists/pharmacology , Adrenergic beta-Agonists/therapeutic use , Adrenergic beta-Antagonists/pharmacology , Adult , Analysis of Variance , Atenolol/pharmacology , Bisoprolol/pharmacology , Celiprolol/pharmacology , Double-Blind Method , Humans , Hypercholesterolemia/complications , Hypertension/complications , Male , Middle Aged , Propranolol/pharmacology
20.
J Hum Hypertens ; 13(1): 47-53, 1999 Jan.
Article En | MEDLINE | ID: mdl-9928752

The aim of this study was to compare the effects of ramipril and nitrendipine chronic treatment on urinary albumin excretion (UAE) in hypertensive patients with type II non-insulin-dependent diabetes mellitus (NIDDM) and impaired renal function. A 2-year, prospective, randomised study was conducted on 51 men with a diastolic blood pressure (DBP) > or =95 and < or =105 mm Hg, stable NIDDM, serum creatinine between 1.6 and 3.0 mg/dl and persistent UAE >300 and <2000 mg/24 h. After a 3-month preliminary observation period, during which patients began a low-protein, low-sodium diet, and a subsequent 4-week run-in period on placebo, patients were randomly treated with ramipril 5 mg or nitrendipine 20 mg for 2 years. Both drugs similarly reduced BP without affecting glucose homeostasis. In the ramipril group UAE significantly decreased after only 3 months of treatment, whereas in the nitrendipine group a significant although lesser reduction in UAE was observed only after 1 year. During the second year the UAE% change was not statistically different between the two treatments. Serum creatinine and creatinine clearance showed no significant change with both drugs. The progression of renal insufficiency as assessed by the rate of reduction of creatinine clearance over the 2 years of the study was similar in the ramipril and the nitrendipine groups. In conclusion both ramipril and nitrendipine were associated with a decrease in UAE although such a reduction was earlier and more marked with ramipril. The decline of renal function did not differ significantly between the two treatments.


Albuminuria/drug therapy , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Calcium Channel Blockers/therapeutic use , Diabetes Mellitus, Type 2/complications , Hypertension/complications , Kidney/physiopathology , Nitrendipine/therapeutic use , Ramipril/therapeutic use , Aged , Albuminuria/etiology , Creatinine/blood , Humans , Hypertension/drug therapy , Hypertension/physiopathology , Hypertension/urine , Longitudinal Studies , Male , Middle Aged , Prospective Studies
...